key: cord-0778610-3b63pnxq authors: Gluckman, Ty J.; Bhave, Nicole M.; Allen, Larry A.; Chung, Eugene H.; Spatz, Erica S.; Ammirati, Enrico; Baggish, Aaron L.; Bozkurt, Biykem; Cornwell, William K.; Harmon, Kimberly G.; Kim, Jonathan H.; Lala, Anuradha; Levine, Benjamin D.; Martinez, Matthew W.; Onuma, Oyere; Phelan, Dermot; Puntmann, Valentina O.; Rajpal, Saurabh; Taub, Pam R.; Verma, Amanda K. title: 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee date: 2022-03-16 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2022.02.003 sha: 5d5781b268123d205aac1093ed4c45ec2497fd52 doc_id: 778610 cord_uid: 3b63pnxq nan injury, thrombosis, arrhythmia) have been reported. [4] [5] [6] [7] For some patients infected with SARS-CoV-2, cardiac symptoms (eg, chest pain, shortness of breath, fatigue, and palpitations) persist, lasting months after the initial illness. 8, 9 Laboratory and imaging evidence of myocardial injury and involvement has also been observed in both symptomatic and asymptomatic individuals, 4,10,11 as well as after receipt of the COVID-19 mRNA vaccine. 12 For clinicians treating these individuals, a growing number of questions exist related to evaluation and management of these conditions, as well as safe resumption of physical activity. To help gather further insights, the ACC held a virtual Heart House Roundtable in May 2021, bringing together experts in the following areas: 1) myocarditis; 2) postacute sequelae of SARS-CoV-2 infection (PASC); and 3) sports cardiology. This ECDP represents a key output from that meeting and is intended to serve as a resource for clinicians caring for these patients, largely in the outpatient setting. More specifically, this document attempts to address commonly asked questions regarding the care of adults (aged $18 years) with cardiac symptoms (eg, chest pain, dyspnea, palpitations, syncope) after SARS-CoV-2 infection. In the absence of robust clinical trial data, it is intended to provide practical guidance related to evaluation and management. On May 26, 2021, the ACC's Cardiovascular Conundrums in the COVID-19 Era Roundtable was convened to bring together expert clinicians along with a broad set of stakeholders, including representatives from patient advocacy groups, professional societies, and content experts, to discuss ongoing questions faced by cardiovascular clinicians caring for individuals with COVID-19. Participants in this ACC Heart House Roundtable identified the need for expert consensus guidance regarding the evaluation and management of patients with ongoing cardiac symptoms, along with resumption of physical activity after SARS-CoV-2 infection. Guidance issued in this document was informed by scientific evidence presented and expert opinions considered during the Heart House Roundtable, with additional review and deliberation by the writing committee. Although practical approaches and ongoing gaps in knowledge were discussed during the Roundtable meeting, this document is a separate and independent endeavor that specifically aims to address some of the most common questions that were raised. duration; and echocardiogram with ventricular wall motion abnormalities, often in a noncoronary distribution, and/or abnormal ventricular strain. †Informed by the presentation and may include coronary angiography for suspected acute coronary syndrome or CT pulmonary angiography for suspected pulmonary embolism (see Figure 3 ). ‡Includes other laboratory testing (eg, complete blood count, basic metabolic panel, C-reactive protein), an ambulatory rhythm monitor, a chest X-ray or CT imaging, and pulmonary function tests, along with additional testing for suspected PASC-CVD or PASC-CVS (see Figure 7 ). §For patients with myocarditis, medical therapy may include immunosuppressive drugs (eg, corticosteroids); for patients with pericardial involvement, medical therapy may include nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids (see Figure 3 ). kSee Figure 7 . ¶For patients with PASC-CVS, empiric medical therapy may include a beta-blocker, a non-dihydropyridine calcium-channel blocker, ivabradine, fludrocortisone, and/or midodrine. Historically, viral infection has been regarded as the most common cause of myocarditis. Its reported prevalence is variable and has been estimated at 10 to 106 cases per 100,000 people worldwide, with an annual incidence of 1.8 million. 57 With COVID-19, the true incidence of myocarditis has proven challenging to assess because of ambiguous definitions, evaluation of nonrepresentative populations, and lack of systematic data collection. Although a recent population-based study of young adults (aged <20 years) from 48 U.S. health care organizations estimated the incidence of myocarditis with COVID-19 at about 450 per million, 22 prospective and retrospective studies of hospitalized patients, autopsy data, and CMR suggest that the overall incidence is higher. Fortunately, fulminant myocarditis appears to be quite rare. [53] [54] [55] Echocardiographic data from prospective, crosssectional studies of patients hospitalized for COVID-19 suggest that myocardial dysfunction may be present in up to 40%. 58, 59 This can range from abnormal ventricular strain to overt left and right ventricular systolic dysfunction. 60 Although the latter may be global, wall motion abnormalities with myocarditis are classically segmental in a noncoronary distribution. Pericardial effusion and thickening may also be seen (especially in cases of myopericarditis); however, data on their frequency and degree of overlap with myocarditis are limited. 61 In selected studies, these echocardiographic findings correlate with cTn levels 10 and risk of mortality. 59 Cognizant of 1) the spectrum of myocardial involvement that may be seen with COVID-19; 2) the timing of evaluation relative to SARS-CoV-2 infection; and 3) the range of diagnostic tests available, the writing committee proposes a multiparametric approach to help guide decision-making (see Figure 3 ). This is limited, however, In those with a rising cTn, ECG abnormalities con- In those with suspected myocardial involvement, CMR is recommended if the patient is hemodynamically stable. In symptomatic patients, CMR is the most sensitive method to exclude ischemia and preexisting cardiomy- The treatment approach for symptomatic myocardial patients with myocarditis to: 1) gauge recovery of cardiac function and inflammation; 2) guide heart failure management; and 3) assess prognosis. Myocarditis following COVID-19 mRNA vaccination is an entity separate from but related to myocarditis following SARS-CoV-2 infection. 119 In case reports and case series of vaccine-associated myocarditis, chest pain has been noted in the vast majority, 12 occurring most commonly 2-3 days after the second mRNA vaccine dose. 12 Much less often, it has been observed after the first dose. 12 Available data from the U.S. Vaccine Adverse Event Reporting System suggest that myocarditis following COVID-19 mRNA vaccination is rare. 12 Although the exact mechanism of vaccine-associated myocarditis is not currently known, it has been hypothesized that molecular mimicry (between the spike protein of SARS-CoV-2 and self-antigens), autoantibody formation, triggered immune dysregulation with activation of natural killer cells, and a dysregulated cytokine and immune response to mRNA may all play a role. 12, 129, 130 The observed male predominance may also be related to sex hormone differences in immune response. 131 Endomyocardial biopsy has been reported in only a small number of cases of postvaccination myocarditis. In 2 cases, specimens showed inflammatory infiltrates largely consisting of T cells and macrophages, admixed with eosinophils, B cells, and plasma cells. 18 In other cases, biopsy has failed to demonstrate myocardial infiltrates 132 and evidence of myocarditis. 133 Figure 4 ). 123 In addition, beyond helping to mitigate the risk of hospitalization and death related to SARS-CoV-2 infection, vaccination can help reduce the risk of related complications, such as myocarditis, MIS-A, 139 and PASC. 12, 140 Evaluation and Management In general, vaccine-associated myocarditis should be diagnosed, categorized, and treated in a manner analogous to myocarditis following SARS-CoV-2 infection (see Patients with this condition commonly experience wide-ranging symptoms, including fatigue, cognitive dysfunction, sleep disturbance, and exercise intolerance. Reported symptoms encompass nearly every organ system, with varying impacts on quality of life (see Figure 5 ). PASC-CVD refers to a broad group of cardiovascular conditions that manifest $4 weeks after SARS-CoV-2 infection. Timing, however, may vary depending upon initial illness severity. PASC-CVD includes, but is not limited to, The clustering of exercise intolerance with symptoms of fatigue, postexertional malaise, and brain fog has prompted comparison of PASC to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). 168 ME/CFS is defined by a triad of symptoms: 1) substantial impairment in the ability to function at home or at work, lasting for more than 6 months, accompanied by profound fatigue of new or definite onset (but not lifelong) that is not appreciably alleviated by rest; 2) postexertional malaise; and 3) unrefreshing sleep. 169 Patients must also have either orthostatic intolerance or cognitive impairment. 169 Although ME/CFS has been reported after infection (eg, Epstein-Barr virus, cytomegalovirus, human herpesvirus 6 and 8, Borrelia burgdorferi), a direct link between infection and prolonged symptoms is usually lacking. Even though some have suggested that ME/CFS and PASC share a common pathophysiology (including immune and metabolic system dysregulation), ME/CFS still remains poorly understood, with relatively few practitioners experienced in diagnosing and treating it. Data suggest that as many as 10%-30% of individuals may experience prolonged symptoms following SARS-CoV-2 infection, a subset of which may relate to the cardiovascular system. 9 In a community sample of >500,000 U.K. residents participating in the REACT-2 (Real-Time Assessment of Community Transmission-2) study, onethird of those self-reporting a history of COVID-19 noted at least one symptom (such as shortness of breath, chest pain, or tiredness) and nearly 15% experienced 3 or more symptoms lasting 12 weeks or longer. 153 Similarly, in a study of Swedish health care workers, 10% reported persistent symptoms more than 8 months following mild infection, with dyspnea and palpitations among the top 10 symptoms reported. 151 Finally, in a study of patients Figure 6 ). 164 In fact, this is considered to be one of the key mechanisms underlying POTS. 184 Importantly, although exercise therapy is essential to recovery, standard exercise involving upright activity (eg, walking, jogging) may worsen symptoms of PASC-CVS, inflammation may also increase the potential for coronary vasospasm. 177, 190, 191 In a study of 11 PASC patients with angina and suspected ischemia, invasive coronary vasomotion testing revealed abnormal endothelial-dependent responses to acetylcholine in 82%; this was driven by a mix of endothelial-dependent and endothelialindependent (smooth muscle) effects. 192 Other potential contributors include myocardial and/or pericardial disease that may have gone undetected with initial testing. Finally, chest pain is a common feature of POTS and ME/CFS; the underlying mechanisms for this, however, remain poorly understood. Shortness of breath, cough, and pleuritic chest pain represent commonly reported symptoms with PASC. Some may also note inability to take a full breath or air hunger with exertion, prompting interruption of ambulation on flat ground and/or basic activities of daily living. Although dyspnea is common in patients with myocardial ischemia, heart failure, and arrhythmia, it may also be seen in those with pulmonary complications following SARS-CoV-2 infection. These include: 1) pulmonary embolism, especially if dyspnea is accompanied by exercise-induced oxygen desaturation, tachycardia, and/or presyncope/syncope; 2) pneumonia; 3) impaired diffusion capacity for carbon monoxide; 4) pulmonary fibrosis; 5) neuromuscular weakness; 6) new or worsening asthma; and 7) bronchial hyperreactivity due to pulmonary vascular inflammation. Among patients hospitalized for COVID-19, lung function impairment is common 6 months after discharge. 33, 193, 194 Unexplained dyspnea (in the absence of cardiopulmonary abnormalities) may also be seen with PASC and may Ultimately, for those with persistent symptoms but without PASC-CVD, additional evaluation for PASC-CVS should be performed, dictated by: 1) the most prominent symptom(s); 2) the patient's baseline characteristics; and 3) the pretest probability of cardiovascular disease (see Figure 7 ). While other potential causes of tachycardia (eg, 158, 192 Invasive coronary vasomotor testing can help with evaluation of the latter; however, referral to a specialized center may be needed. Given the proclivity of SARS-CoV-2 infection to involve the lungs, initial diagnostic testing should focus on exclusion of pulmonary processes. Most commonly, this involves a chest X-ray and/or a noncontrast CT scan of the lungs, along with pulmonary function testing. If should be based on current guidelines; those related to PASC-CVS largely depend on the underlying symptom(s). For those with tachycardia, exercise/orthostatic intolerance, and/or deconditioning, interventions normally used for POTS should be considered. The benefits of exercise training following bedrest deconditioning 187, 198 and that resulting from POTS 184, 185, 199 However, not all exercise is problematic. 201 Instead of upright exercise, recumbent or semi-recumbent exercise (eg, rowing, swimming, or cycling) is recommended initially (see Figure 8) , with transition to upright exercise over time as orthostatic intolerance resolves. 185, 198, 202 In addition, exercise duration should be short initially, increasing gradually as functional capacity increases. Exercise intensity should also be at a submaximal level, sustained for the duration of exercise, with natural increases as tolerance improves. For example, patients should generally start with daily recumbent exercise for only w5-10 minutes at a level that allows them to speak in full sentences; thereafter, gradual increases in exercise (eg, 2 additional minutes of exercise per day each week) are recommended (see Figure 8 ). These principles help to avoid worsening fatigue or setbacks and usually can be applied to all patients with deconditioning, regardless of age and whether POTS is present. 203 This type of program has also been shown to support long-term cardiovascular health. 204 Ultimately, a formalized exercise program should be initiated. For some patients, this may be best done in a supervised setting with a physical therapist; alternatively, specific instructions may be provided on how to implement such a program at home or in a gym. 164, 199 Given the reduction in plasma volume that follows deconditioning, 183 For patients with dyspnea unrelated to cardiovascular disease, consideration should be given to pulmonary consultation to guide further evaluation and management. Importantly, low preload states can result in dyspnea, underscoring the importance of volume loading and recumbent exercise, as described in the tachycardia and exercise intolerance section. 212 Physical therapy that incorporates aerobic training and diaphragmatic breathing exercises can be a helpful adjunct to address underlying ventilatory abnormalities and muscle dysfunction, 196, 213 as noted with other pulmonary diseases. Both PASC-CVD and PASC-CVS may be encountered after SARS-CoV-2 infection, with varying effects on quality of life. Because much remains to be learned about these conditions, 214 substantial opportunities exist to better understand their epidemiology, underlying mechanisms, and best approaches for evaluation and management. 214 In addition, little is also currently known about the incidence of PASC in children, those with vaccine breakthrough infection, and those affected by newer SARS-CoV-2 variants (eg, Delta, Omicron). All of this underscores the need to conduct studies that leverage rigorous data collection and precise enrollment to define best practices for distinct phenotypes. 172, 215, 216 Given that the total cost of PASC to patients and their families, the health care system, payers, and society at large is likely to be substantial, there is a critical need to identify ways to better meet the needs of those with this condition. evidence-based framework to guide RTP evaluation. Multiple studies have affirmed that myocarditis is a common cause of sudden cardiac death in athletes. 225 Unfortunately, early RTP recommendations related to COVID-19 were limited by: 1) an uncertain prevalence of Abnormal ECG: 3 (5%) Abnormal cTn: 1 (2%) Abnormal echocardiogram: 6 (11%) Any CMR abnormality (of 8 tested): 2 (25%) *Studies included standard triad testing (ECG, cTn, and echocardiogram) or standard triad testing along with mandated CMR. CMR ¼ cardiac magnetic resonance imaging; cTn ¼ cardiac troponin; ECG ¼ electrocardiogram; LGE ¼ late gadolinium enhancement; NA ¼ not available; RV ¼ right ventricle. reports of significant myocardial injury and poor outcomes among some hospitalized patients. 10,11 Initial reports detailing the prevalence of myocardial involvement in athletes with COVID-19 were largely single-center studies using CMR as an additional screening tool. In the first published case series of largely asymptomatic U.S. collegiate athletes who underwent triad testing along with screening CMR, 223 Clinical myocarditis: 9 (0.6%) *N ¼ 62 with moderate COVID-19 symptoms or abnormal baseline cardiac testing. †Myocardial involvement defined as: 1) definite: T1 abnormality þ LGE and T2 abnormality, or T2 abnormality þ additional supportive criteria (LVEF #45%, pericardial effusion or enhancement, or cTn level above the 99th percentile upper reference limit); 2) probable: T1 abnormality þ LGE and 1 or more supportive criterion; or 3) possible: isolated T1 abnormality or LGE. ‡Myocarditis defined as clinical or subclinical (CMR-defined myocardial inflammation in the absence of symptoms suggestive of clinical myocarditis and elevated cTn). CMR ¼ cardiac magnetic resonance imaging; cTn ¼ cardiac troponin; ECG ¼ electrocardiogram; LGE ¼ late gadolinium enhancement; LVEF ¼ left ventricular ejection fraction; NA ¼ not available. that participated. Results were also remarkably comparable to those of the Outcomes Registry for Cardiac Conditions in Athletes and the professional athlete registries, as only 9 athletes (0.6%) had findings consistent with clinical myocarditis. athletes. 234 A recent study also noted comparable rates of focal LGE at RV insertion points among athletes with SARS-CoV-2 (22%) and noninfected athlete controls (24%). 224 Third, parametric mapping requires a high level of expertise. Accordingly, marked heterogeneity in reported CMR results from different centers may relate to regional variations in CMR performance and interpreter bias, given the lack of blinded review by an independent core laboratory. Fourth, the absence of an appropriate control group limits the interpretation of clinical significance and application of these CMR findings in a testing algorithm. Finally, cost, limited availability, and equi- Historically, an athlete has been defined as an individual who places a high premium on exercise training, competition, and sports achievement. 235 Individuals who self-identify as athletes extend across the age spectrum, from youth sports (aged <18 years) to masters-level (aged >35 years) exercise enthusiasts. 235 Previous recommendations were given to individual athletic populations recovering from COVID-19, with encouragement to observe younger athletes (aged <21 years) for several weeks to monitor for the development of MIS-C. 236, 237 Masters-level athletes may also have traditional risk factors for cardiovascular disease, 238 activity restriction is no longer necessary (see Figure 9 ). For athletes with cardiopulmonary symptoms, initial evaluation should ideally be with an ECG, cTn (highsensitivity assay preferred), and an echocardiogram (see Figure 9 ). The presence of abnormal findings with triad testing or persistence of cardiopulmonary symptoms (specifically chest pain or tightness, palpitations, or syncope) after initial testing suggest that additional kMaximal-effort exercise testing should be deferred until myocarditis has been excluded. Use of CMR to screen athletes who are asymptomatic or with non-cardiopulmonary symptoms is likely to be low yield. Such testing may, however, be considered in those with abnormal triad testing along with increased concern of cardiac involvement or in those with either persistent or new cardiopulmonary symptoms. Importantly, further research is needed to better understand the significance of other forms of myocardial involvement detected by CMR, 68, 223 particularly in the absence of symptoms. It is likely that clinicians will increasingly see asymp- infection (see Figure 9 ). In general, routine surveillance monitoring and/or addi- Myocarditis and other myocardial involvement n Myocarditis is defined by: 1) cardiac symptoms (eg, chest pain, dyspnea, palpitations, syncope); 2) an elevated cTn; and 3) abnormal electrocardiographic, echocardiographic, CMR, and/or histopathologic findings on biopsy or postmortem evaluation in the absence of flow-limiting coronary artery disease. n When there is increased suspicion for cardiac involvement with COVID-19, initial testing should consist of an ECG, measurement of cTn (preferably using a high-sensitivity assay), and an echocardiogram. n Cardiology consultation is recommended for those with a rising cTn and/or ECG or echocardiographic abnormalities concerning for myocarditis. n CMR is recommended in hemodynamically stable patients with suspected myocarditis. n Hospitalization is recommended for patients with definite myocarditis that is either mild or moderate in severity, ideally at an advanced heart failure center. Patients with fulminant myocarditis should be managed at centers with an expertise in advanced heart failure, mechanical circulatory support, and other advanced therapies. n Patients with myocarditis and COVID-19 pneumonia (with an ongoing need for supplemental oxygen) should be treated with corticosteroids. n For patients with suspected pericardial involvement, treatment with NSAIDs, colchicine, and/or prednisone is reasonable. n Intravenous corticosteroids may be considered in those with suspected or confirmed COVID-19 myocarditis with hemodynamic compromise or MIS-A. Empiric use of corticosteroids may also be considered in those with biopsy evidence of severe myocardial infiltrates or fulminant myocarditis, balanced against infection risk. n As appropriate, guideline-directed medical therapy for heart failure should be initiated and continued after discharge. n Myocarditis following COVID-19 mRNA vaccination is rare. The highest observed rates have been in young male individuals (aged 12-17 years) after the second vaccine dose. n COVID-19 vaccination is associated with a very favorable benefit-to risk ratio for all age and sex groups evaluated thus far. n In general, vaccine-associated myocarditis should be diagnosed, categorized, and treated in a manner analogous to myocarditis following SARS-CoV-2 infection. PASC n PASC is defined as a constellation of new, returning, or persistent health problems experienced by individuals 4 or more weeks after SARS-CoV-2 infection. n PASC-CVD refers to a broad group of cardiovascular conditions that include, but are not limited to, myocarditis and other forms of myocardial involvement, pericarditis, new or worsening myocardial ischemia, microvascular dysfunction, nonischemic cardiomyopathy, thromboembolism, cardiovascular sequelae of pulmonary disease, and arrhythmia. n PASC-CVS is a heterogeneous disorder that includes widely-ranging cardiovascular symptoms, without objective evidence of cardiovascular disease using standard diagnostic testing. Common symptoms include tachycardia, exercise intolerance, postexertional malaise, palpitations, chest pain, and dyspnea. n For patients with cardiovascular symptoms and suspected PASC, a reasonable initial testing approach includes: 1) basic laboratory testing (including cTn); 2) an ECG; 3) an echocardiogram; 4) an ambulatory rhythm monitor; 5) chest imaging (X-ray and/or CT); and/or 6) pulmonary function tests. n Cardiology consultation is recommended for patients with PASC that have: 1) abnormal cardiac test results; 2) known cardiovascular disease with new or worsening symptoms or signs; 3) documented cardiac complications during SARS-CoV-2 infection; and/or 4) persistent cardiopulmonary symptoms that are not otherwise explained. n Recumbent or semi-recumbent exercise (eg, rowing, swimming, or cycling) is recommended initially for PASC-CVS patients with tachycardia, exercise/orthostatic intolerance, and/or deconditioning, with transition to upright exercise as orthostatic intolerance improves. Exercise duration should also be short (5-10 minutes/day) initially, with gradual increases as functional capacity improves. n Salt and fluid loading represent nonpharmacological interventions that may provide symptomatic relief for patients with tachycardia, palpitations, and/or orthostatic hypotension. Beta-blockers, nondihydropyridine calcium-channel blockers, ivabradine, fludrocortisone, and midodrine may be used empirically as well. RTP n Athletes who are asymptomatic after recent SARS-CoV-2 infection may resume exercise training after 3 days of exercise abstinence during self-isolation. n Athletes with mild or moderate non-cardiopulmonary symptoms after recent SARS-CoV-2 infection may resume exercise training after their symptoms have resolved. n Athletes with remote infection ($3 months) without ongoing cardiopulmonary symptoms may resume exercise training without the need for additional testing. n Athletes recovering from COVID-19 with ongoing cardiopulmonary symptoms (chest pain/tightness, palpitations, or syncope) and/or those requiring hospitalization with increased suspicion for cardiac involvement should undergo triad testing (ECG, cTn, and echocardiogram). Triad testing should also be performed in those developing new cardiopulmonary symptoms after resumption of exercise training. n CMR is recommended if triad testing is abnormal or cardiopulmonary symptoms persist. n Athletes with myocarditis should abstain from exercise for 3-6 months. n Maximal-effort exercise testing and/or an ambulatory rhythm monitor may be helpful in the evaluation of athletes with: 1) persistent cardiopulmonary symptoms and 2) either normal CMR or CMR that demonstrates other forms of myocardial (or pericardial) involvement. Maximal-effort exercise testing should only be performed, however, after myocarditis has been excluded with CMR. n CMR to screen athletes who are asymptomatic or with non-cardiopulmonary symptoms is likely to be low yield. n Repeat cardiac testing is not warranted in athletes with recurrent COVID-19 in the absence of cardiopulmonary symptoms. Decision-making regarding RTP in PASC should be informed by whether cardiopulmonary symptoms are present. If they are, a similar approach to that recommended above should be pursued, using: 1) triad testing; 2) CMR (if appropriate); and 3) limitation of strenuous physical activity (see Figure 9 ). If PASC-CVD is excluded, further evaluation with CPET and pulmonary function testing may be considered as part of the PASC-CVS evaluation. Although individuals with PASC may be unable to readily resume their prior activity levels, structured and individualized graded exercise, as recommended in the PASC section, should be performed throughout the recovery process. As our understanding of the cardiovascular effects of COVID-19 evolves, it is anticipated that RTP guidance for athletes will change as well. Several areas of future investigation are noteworthy. First, although it is extremely reassuring that adverse events among infected athletes have been rare, further study is needed to determine how long recovery takes after documented abnormalities and the role that imaging can play in guiding this. Second, the risks and benefits of exercise resumption among patients with PASC remains to be rigorously defined. Given the therapeutic role of training in this population, further investigation into associated risks will be particularly important. Third, our current knowledge stems largely from study of those infected with early variants of SARS-CoV-2. Further research is needed to understand whether the extent and severity of cardiac involvement is different with Delta, Omicron, and other variants. It will also be important to define the temporal pattern of myocardial involvement, along with predictors of myocarditis progression and resolution with SARS-CoV-2 and other common respiratory viral pathogens. Finally, widespread resumption of competitive sports will come with rare but devastating adverse events, including sudden cardiac death, that well predate COVID-19. Accordingly, it will be important to limit automatic attribution of such events to COVID-19 without further detailed evaluation. This ECDP provides a framework for evaluation and management of adults with cardiovascular sequelae following SARS-CoV-2 infection. Guidance provided is based on expert consensus, with multiple key takeaways (see Table 3 ). Importantly, it is intended to help clinicians understand not only when testing may be warranted, but also when it is not. Given that it reflects the current state of knowledge through early 2022, it is anticipated that recommendations will change over time as our understanding evolves. For both myocarditis and PASC, there exist significant opportunities to better understand their epidemiology, underlying mechanisms, predisposing risk factors, and preferred approaches for evaluation and management. For RTP, there is a need to more rigorously define how long cardiovascular abnormalities persist and the relative benefits of exercise training in those with PASC. Beyond the indirect effects and undesirable consequences that COVID-19 has had on care delivery, it also remains to be seen how new variants and vaccine breakthrough infection will affect cardiovascular health. Improved understanding of the associated near-and longterm consequences will be key in helping to improve clinical outcomes. 2019 methodology for creating expert consensus decision pathways: a report of the American College of Cardiology Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week Electrocardiographic findings in coronavirus disease-19: insights on mortality and underlying myocardial processes Cardiac and arrhythmic complications in patients with COVID-19 Thrombosis in hospitalized patients with COVID-19 in a New York City health system Persistent symptoms in patients after acute COVID-19 Sequelae in adults at 6 months after COVID-19 infection Characterization of myocardial injury in patients with COVID Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) Myocarditis with COVID-19 mRNA vaccines Coronavirus disease-2019 and heart failure: a scientific statement from the Heart Failure Society of America World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus Post_COVID-19_condition-Clinical_case_definition-2 COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines Fourth universal definition of myocardial infarction Myocarditis after COVID-19 mRNA vaccination Combined cardiac fluorodeoxyglucose-positron emission tomography/magnetic resonance imaging assessment of myocardial injury in patients who recently recovered from COVID-19 Cardiovascular magnetic resonance imaging in children after recovery from symptomatic COVID-19 or MIS-C: a prospective study Multimodality cardiac evaluation in children and young adults with multisystem inflammation associated with COVID-19 Incidence of venous thromboembolism among patients with severe COVID-19 requiring mechanical ventilation compared to other causes of respiratory failure: a prospective cohort study Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V) Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations A histopathologic definition and classification Diagnosis of myocarditis: death of Dallas criteria Cardiovascular magnetic resonance in myocarditis: a JACC White Paper Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations CMR sensitivity varies with clinical presentation and extent of cell necrosis in biopsy-proven acute myocarditis Attributes and predictors of long COVID Virus and the heart Letter: grading of angina pectoris UK Research and Innovation. MRC dyspnoea scale / MRC breathlessness scale The post-COVID-19 functional status scale: a tool to measure functional status over time after COVID-19 Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) COVID-19 and myocarditis: a systematic review and overview of current challenges COVID-19-associated myocarditis presenting as new-onset heart failure and atrial fibrillation Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: multicenter Lombardy registry Global, regional, and national burden of myocarditis and cardiomyopathy Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study Incremental prognostic value of biventricular longitudinal strain and high-sensitivity troponin I in COVID-19 patients Echocardiographic manifestations in COVID-19: a review Pericardial diseases in COVID19: a contemporary review Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging COVID-19: myocardial injury in survivors Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance Prospective casecontrol study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers T2-mapping increase is the prevalent imaging biomarker of myocardial involvement in active COVID-19: a Cardiovascular Magnetic Resonance study Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the Big Ten COVID-19 Cardiac Registry Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe Early echocardiographic and cardiac MRI findings in multisystem inflammatory syndrome in children Imaging of multisystem inflammatory disease in children (MIS-C) associated With COVID-19 Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging High prevalence of pericardial involvement in college student athletes recovering from COVID-19 Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab Myocarditis and inflammatory cardiomyopathy: current evidence and future directions Cardiogenic shock and hyperinflammatory syndrome in young males with COVID-19 Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis COVID-19 myocarditis: quantitative analysis of the inflammatory infiltrate and a proposed mechanism Delayed-onset myocarditis following COVID-19 Description and proposed management of the acute COVID-19 cardiovascular syndrome Myocardial localization of coronavirus in COVID-19 cardiogenic shock Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC review topic of the week Pathological findings of COVID-19 associated with acute respiratory distress syndrome Unexpected features of cardiac pathology in COVID-19 infection Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study COVID-19 autopsies COVID-19 autopsy in people who died in community settings: the first series Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities Endothelial cell infection and endotheliitis in COVID-19 Forty postmortem examinations in COVID-19 patients Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series SARS-CoV-2-related deaths in routine forensic autopsy practice: histopathological patterns Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Global evaluation of echocardiography in patients with COVID-19 Cardiac performance in patients hospitalized with COVID-19: a 6 month follow-up study Society for Cardiovascular Magnetic Resonance (SCMR) Cardiovascular magnetic resonance for patients with COVID Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society position statement on endomyocardial biopsy The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology High-dimensional characterization of post-acute sequelae of COVID-19 Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association ESC guidelines for the diagnosis and management of pericardial diseases: the Task Force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS) Coronavirus disease 2019 acute myocarditis and multisystem inflammatory syndrome in adult intensive and cardiac care units Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults. Circulation Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US Military Surveillance for adverse events after COVID-19 mRNA vaccination COVID-19 vaccination-associated myocarditis in adolescents Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: ppdate from the Advisory Committee on Immunization Practices -United States Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Myocarditis after COVID-19 vaccination in a large health care organization Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: a comparison of completeness and timeliness of two methods. medRxiv SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms The quest for new approaches in myocarditis and inflammatory cardiomyopathy Myocarditis after BNT162b2 and mRNA-1273 vaccination Myocarditis temporally associated with COVID-19 vaccination Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction? Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine Association between COVID-19 and myocarditis using hospital-based administrative data -United States Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting Striking similarities of multisystem inflammatory syndrome in children and a myocarditis-like syndrome in adults: overlapping manifestations of COVID-19 Long COVID-19 or post-acute sequelae of SARS-CoV-2 infection in children, adolescents, and young adults Centers for Disease Control and Prevention. Summary document for interim clinical considerations for use of COVID-19 vaccines currently authorized or approved in the United States Post-acute COVID-19 syndrome NICE guideline on long COVID Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study Royal College of General Practitioners, and Scottish Intercolleciate Guidelines Network COVID-19 rapid guideline: managing the long-term effects of COVID Post-intensive care syndrome and COVID-19 -implications post pandemic Clinical characteristics of multisystem inflammatory syndrome in adults: a systematic review Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection -United Kingdom and United States Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv Symptom persistence despite improvement in cardiopulmonary health-insights from longitudinal CMR, CPET and lung function testing post-COVID-19. ECli-nicalMedicine Management of post-acute covid-19 in primary care Late phase of COVID-19 pandemic in general cardiology. a position paper of the ESC Council for Cardiology Practice Laboratory and imaging evaluation of cardiac involvement in patients with post-acute COVID-19 Characteristics of patients referred to a cardiovascular disease clinic for post-acute sequelae of SARS-CoV-2 infection. medRxiv Echocardiographic comparison of COVID-19 patients with or without prior biochemical evidence of cardiac injury after recovery Follow up of patients with severe coronavirus disease 2019 (COVID-19): pulmonary and extrapulmonary disease sequelae Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial Assessment of cognitive function in patients after COVID-19 infection Longhaul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience Postural orthostatic tachycardia syndrome: JACC focus seminar Postural orthostatic tachycardia syndrome: the Mayo Clinic experience Long-COVID postural tachycardia syndrome: an American Autonomic Society statement Post-COVID-19 tachycardia syndrome: a distinct phenotype of post-acute COVID-19 syndrome Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome Beyond myalgic encephalomyelitis/ chronic fatigue syndrome: an IOM report on redefining an illness COVID-19 survivors' reports of the timing, duration, and health impacts of post-acute sequelae of SARS-CoV-2 (PASC) Infection. medRxiv Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA) Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): a longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. medRxiv Diverse functional autoantibodies in patients with COVID-19 Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination. medRxiv Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV Study Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study Assessment of functional capacity with cardiopulmonary exercise testing in non-severe COVID-19 patients at three months follow-up. medRxiv Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors Dysautonomia": a plea for precision Cardiac atrophy after bed-rest deconditioning: a nonneural mechanism for orthostatic intolerance Cardiac origins of the postural orthostatic tachycardia syndrome Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome Cardiovascular deconditioning produced by 20 hours of bedrest with head-down tilt (-5 degrees) in middleaged healthy men Response to exercise after bed rest and after training Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing Long COVID in a prospective cohort of home-isolated patients Endothelial dysfunction in patients with chest pain and normal coronary arteries An EAPCI expert consensus document on ischaemia with nonobstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation endorsed by Coronary Vasomotor Disorders International Study Group Myocardial ischaemia of non-obstructive origin as a cause of new onset anginal chest pain in the long COVID syndrome 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge Lung function deficits and symptom burden in survivors of COVID-19 requiring mechanical ventilation Exercise ventilatory inefficiency in post-COVID-19 syndrome: insights from a prospective evaluation Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease AHA/ ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Effect of rowing ergometry and oral volume loading on cardiovascular structure and function during bed rest The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting NICE advises against using graded exercise therapy for patients recovering from COVID-19 What are the recommendations for returning athletes who have experienced long term COVID-19 symptoms Exercise and non-pharmacological treatment of POTS Reversing the cardiac effects of sedentary aging in middle age-a randomized controlled trial: implications for heart failure prevention Impact of lifelong exercise "dose" on left ventricular compliance and distensibility Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension Lowdose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure Roles of dietary inorganic nitrate in cardiovascular health and disease Longterm L-arginine supplementation improves smallvessel coronary endothelial function in humans Dyspnea in chronic low ventricular preload states Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings The longterm sequelae of COVID-19: an international consensus on research priorities for patients with preexisting and new-onset airways disease -million-invested-tostudy-long-term-impact-of-covid-19-on-heart-andbrain-health 216. National Institutes of Health. NIH builds large nationwide study population of tens of thousands to COVID-19 and cardiovascular disease Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic Resurgence of sport in the wake of COVID-19: cardiac considerations in competitive athletes Exercise in the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) era: a question and answer session with the experts endorsed by the section of Sports Cardiology & Exercise of the European Association of Preventive Cardiology (EAPC) A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) infection Coronavirus disease 2019 and the athletic heart: emerging perspectives on pathology, risks, and return to play Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR) Myocarditis in athletes is a challenge: diagnosis, risk stratification, and uncertainties Cardiac magnetic resonance findings in patients recovered from COVID-19: initial experiences in elite athletes Cardiac involvement in consecutive elite athletes recovered from Covid-19: a magnetic resonance study Cardiovascular evaluation after COVID-19 in 137 collegiate athletes: results of an algorithm-guided screening Findings from cardiovascular evaluation of National Collegiate Athletic Association Division I collegiate studentathletes after asymptomatic or mildly symptomatic SARS-CoV-2 infection Health experts worry coronavirus could cause lasting heart complications for athletes The Big Ten conference adopts stringent medical protocols; football season to resume Red Sox pitcher Eduardo Rodriguez confirms he's dealing with heart issue stemming from COVID-19 infection Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the Myocardial fibrosis in athletes-Current perspective Sports cardiology: core curriculum for providing cardiovascular care to competitive athletes and highly active people Multisystem inflammatory syndrome in U.S. children and adolescents Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune responses Prevalence of subclinical coronary artery disease in Masters Endurance Athletes with a low atherosclerotic risk profile Longterm incidence of atrial fibrillation and stroke among cross-country skiers Centers for Disease Control and Prevention Quarantine and Isolation. Accessed Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes Lifelong physical activity regardless of dose is not associated with myocardial fibrosis Differentiating exerciseinduced cardiac adaptations from cardiac pathology: the "grey zone" of clinical uncertainty Differentiation between athlete's heart and dilated cardiomyopathy in athletic individuals Expert Consensus Decision Pathway, athletes, cardiovascular diseases, chest pain, COVID-19, myocarditis, SARS-CoV-2, sports medicine 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults To avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee, all members of the writing committee, as well as peer reviewers of the document, are asked to disclose all current healthcare-related relationships, including those existing 12 months before initiation of the writing effort.